Sage Therapeutics’ rare disease drug meets main goal in mid-stage study
By Thomson ReutersJun 11, 2024 | 5:51 AM
(Reuters) – Sage Therapeutics said on Tuesday its experimental drug met the main goal of a mid-stage study in patients with a type of rare disease known as Huntington’s disease.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
